Welcome to our dedicated news page for NeuroBo Pharmaceuticals (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on NeuroBo Pharmaceuticals .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroBo Pharmaceuticals 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroBo Pharmaceuticals 's position in the market.
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) will present pre-clinical data on its cardiometabolic assets, DA-1241 and DA-1726, at the EASL Congress 2024 and the ADA 84th Scientific Sessions in June. With enrollment completion for the Phase 2a trial of DA-1241 and dosing of the first patient in the Phase 1 trial of DA-1726, NeuroBo is advancing well towards treating MASH and obesity. The company aims to dose the first patient in the multiple ascending dose Part 2 and release top-line data in the third quarter of 2024 and the first quarter of 2025, respectively.